News
The FDA has removed the recommended pause in the use of Valneva’s chikungunya vaccine Ixchiq in individuals aged 60 years and older.
The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...
Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...
Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...
The FDA decision follows the announcement in July by the European Medicines Agency (EMA) 1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough ...
Pharmaceutical Technology on MSN5d
FDA removes Ixchiq partial pause but tightens vaccine’s use
The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older ...
MedPage Today on MSN6d
FDA Lifts Pause on Chikungunya Vaccine in Older Adults, With Revised Labeling
"Based on the available data, and its benefit-risk assessment, FDA has removed the recommended pause in the use of Ixchiq in ...
Back in May, the regulator recommended against the continued use of the vaccine, Ixchiq, in people 65 and older as it weighed reports of serious adverse events in elderly people.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback